A better understanding of the biology of chronic lymphocytic leukaemia (CLL) has led to significant improvements in treatment strategies and outcomes for patients with CLL. In this podcast, we talk to Professor Peter Hillmen from the University of Leeds about how the introduction of novel therapies for CLL has influenced treatment goals. He also provides his views on the future clinical utility of minimal residual disease assessment to inform treatment.
This podcast was sponsored by Janssen. The content is based on published studies and the opinions of independent experts. The views expressed are not necessarily those of Janssen.
PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING (available from www.janssen.com.au/imbruvica_PI).